atai Life Sciences (ATAI) Competitors $2.78 +0.03 (+0.91%) Closing price 03:59 PM EasternExtended Trading$2.76 -0.01 (-0.36%) As of 04:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATAI vs. SPRY, ADPT, IMCR, SDGR, EWTX, BHVN, ETNB, ANIP, VERA, and JANXShould you be buying atai Life Sciences stock or one of its competitors? The main competitors of atai Life Sciences include ARS Pharmaceuticals (SPRY), Adaptive Biotechnologies (ADPT), Immunocore (IMCR), Schrodinger (SDGR), Edgewise Therapeutics (EWTX), Biohaven (BHVN), 89BIO (ETNB), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. atai Life Sciences vs. Its Competitors ARS Pharmaceuticals Adaptive Biotechnologies Immunocore Schrodinger Edgewise Therapeutics Biohaven 89BIO ANI Pharmaceuticals Vera Therapeutics Janux Therapeutics ARS Pharmaceuticals (NASDAQ:SPRY) and atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Is SPRY or ATAI more profitable? atai Life Sciences has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -16.11%. ARS Pharmaceuticals' return on equity of -6.94% beat atai Life Sciences' return on equity.Company Net Margins Return on Equity Return on Assets ARS Pharmaceuticals-16.11% -6.94% -5.60% atai Life Sciences N/A -102.10%-77.55% Do analysts recommend SPRY or ATAI? ARS Pharmaceuticals presently has a consensus price target of $31.00, suggesting a potential upside of 88.05%. atai Life Sciences has a consensus price target of $9.00, suggesting a potential upside of 224.32%. Given atai Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe atai Life Sciences is more favorable than ARS Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ARS Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17atai Life Sciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Does the media favor SPRY or ATAI? In the previous week, atai Life Sciences had 5 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 18 mentions for atai Life Sciences and 13 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 0.78 beat atai Life Sciences' score of 0.42 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive atai Life Sciences 6 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders hold more shares of SPRY or ATAI? 68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 28.4% of atai Life Sciences shares are owned by institutional investors. 33.5% of ARS Pharmaceuticals shares are owned by insiders. Comparatively, 26.8% of atai Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more volatility and risk, SPRY or ATAI? ARS Pharmaceuticals has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Comparatively, atai Life Sciences has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500. Which has stronger earnings and valuation, SPRY or ATAI? ARS Pharmaceuticals has higher revenue and earnings than atai Life Sciences. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than atai Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioARS Pharmaceuticals$89.15M18.16$8M-$0.16-103.03atai Life Sciences$310K1,793.37-$149.27M-$0.91-3.05 SummaryARS Pharmaceuticals beats atai Life Sciences on 9 of the 16 factors compared between the two stocks. Get atai Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATAI vs. The Competition Export to ExcelMetricatai Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$550.93M$3.90B$5.54B$8.95BDividend YieldN/A1.28%5.38%4.08%P/E Ratio-3.0535.6227.4020.04Price / Sales1,793.37101.06419.46118.60Price / CashN/A23.8136.6357.47Price / Book4.024.398.085.67Net Income-$149.27M$189.47M$3.16B$248.47M7 Day Performance23.33%-2.94%2.12%2.90%1 Month Performance18.09%-3.93%4.43%5.75%1 Year Performance116.80%8.45%35.62%21.36% atai Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATAIatai Life Sciences3.1375 of 5 stars$2.78+0.9%$9.00+224.3%+111.5%$550.93M$310K-3.0580News CoverageAnalyst ForecastOptions VolumeHigh Trading VolumeSPRYARS Pharmaceuticals3.1082 of 5 stars$16.51+4.5%$31.00+87.8%+93.4%$1.62B$89.15M-102.9290Insider TradeADPTAdaptive Biotechnologies3.4511 of 5 stars$10.50+1.2%$10.57+0.7%+240.7%$1.60B$178.96M-10.97790News CoverageGap UpIMCRImmunocore2.5334 of 5 stars$31.11-0.7%$58.89+89.3%-5.9%$1.56B$310.20M-72.34320SDGRSchrodinger2.8416 of 5 stars$20.33-0.6%$32.80+61.3%+3.1%$1.49B$230.49M-7.74790News CoverageAnalyst ForecastEWTXEdgewise Therapeutics2.7247 of 5 stars$14.13-1.2%$39.78+181.5%-29.2%$1.49BN/A-9.1260News CoverageAnalyst ForecastAnalyst RevisionBHVNBiohaven3.4151 of 5 stars$14.44-0.2%$58.46+304.9%-56.8%$1.48BN/A-1.54239ETNB89BIO1.9391 of 5 stars$9.97-1.1%$26.43+165.1%+32.9%$1.45BN/A-2.9540Positive NewsANIPANI Pharmaceuticals3.716 of 5 stars$65.64+0.1%$80.13+22.1%+4.1%$1.42B$614.38M-51.78600VERAVera Therapeutics3.5427 of 5 stars$21.52+3.2%$65.00+202.0%-32.3%$1.37BN/A-7.1740Positive NewsJANXJanux Therapeutics1.8002 of 5 stars$22.86-3.1%$95.25+316.7%-38.8%$1.35B$10.59M-16.8130 Related Companies and Tools Related Companies SPRY Competitors ADPT Competitors IMCR Competitors SDGR Competitors EWTX Competitors BHVN Competitors ETNB Competitors ANIP Competitors VERA Competitors JANX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATAI) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding atai Life Sciences N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share atai Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATAI Stock Alerts